Teva Pharmaceutical Industries logged a -10.2% change during today's afternoon session, and is now trading at a price of $8.31 per share.
Teva Pharmaceutical Industries shares moved -8.4% over the last 52 weeks, with a high of $11.45 and a low of $6.78. During this time, the stock lagged the S&P 500 index by -3.0%. As of January 2022, the company's 50-day average price is $9.53. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The large-cap Health Care company has 34,004 full time employees and is based in Tel Aviv, Israel. Teva Pharmaceutical Industries has not offered any dividends in the last year.
The Company Has an Irregular Stream of Positive Cash Flows:
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Revenue (MM) | $16,887 | $16,658 | $15,878 | $14,925 |
| Revenue Growth | n/a | -1.36% | -4.68% | -6.0% |
| Gross Margins | 44.6% | 46.4% | 47.8% | 46.7% |
| Gross Margins Growth | n/a | 4.04% | 3.02% | -2.3% |
| Operating Margins | 16.1% | 18.4% | 19.5% | 18.0% |
| Operating Margins Growth | n/a | 14.29% | 5.98% | -7.69% |
| Net Margins | -5.92% | -23.95% | 2.63% | -15.77% |
| Net Margins Growth | n/a | -304.56% | 110.98% | -699.62% |
| Earnings Per Share | -$0.91 | -$3.64 | $0.38 | -$2.1 |
| EPS Growth | n/a | -300.0% | 110.44% | -652.63% |
| Diluted Shares (MM) | 1,091 | 1,095 | 1,107 | 1,111 |
| Free Cash Flow (MM) | $419 | $638 | $236 | $1,042 |
| FCF Growth | n/a | 52.27% | -63.01% | 341.53% |
| Capital Expenditures (MM) | -$119 | -$578 | -$562 | -$548 |
| Net Debt / EBITDA | 7.76 | 5.15 | 4.61 | 4.49 |
Teva Pharmaceutical Industries has negative earnings for the current period, so its trailing twelve month P/E ratio is not meaningful. But based on its EPS guidance of 2.52, the company has a forward P/E ratio of 3.3. In contrast, the Health Care sector's average P/E ratio is 24.45.
On the other hand, Teva Pharmaceutical Industries is possibly undervalued in terms of its net assets because its P/B ratio is 1.2 compared to its sector average of 4.16.
Despite Teva Pharmaceutical Industries's elevated earnings multiple, the company's impressive cash flow trend, decent P/B ratio, and reasonable leverage demonstrate the company may be fairly valued.
Most of the Market Indicators on Teva Pharmaceutical Industries Are Negative:
9 analysts are following Teva Pharmaceutical Industries and have set target prices ranging from $7.0 to $14.0 per share. On average, they have given the company a rating of hold. At the current price of $8.31, TEVA is trading -18.24% away from its average analyst target price of $10.17 per share, implying an analyst consensus of some upside potential for the stock.
